Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead product candidate, TSHA-120, is being developed for the treatment of giant axonal neuropathy, a rare neurodegenerative disorder. The company's pipeline also includes TSHA-102 for Rett syndrome, TSHA-121 for CLN7 disease, TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 deficiency, TSHA-113 for tauopathies, TSHA-106 for Angelman syndrome, and TSHA-114 for fragile X syndrome. Taysha has a research, collaboration, and license agreement with The University of Texas Southwestern Medical Center to support its gene therapy programs.

Taysha Gene Therapies, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol TSHA. The trading currency for its shares is the United States Dollar (USD). As a US-based company, its stock is traded in USD, and financial results are reported in the same currency.

Taysha Gene Therapies operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on developing innovative gene therapies for rare and severe genetic diseases affecting the central nervous system. The company's work involves advanced research in adeno-associated virus (AAV) vectors to deliver therapeutic genes to patients, which is a specialized area within the broader biotech field.

Taysha Gene Therapies is headquartered in Dallas, Texas, United States. The company primarily serves the US market, as indicated by its US region classification. Its gene therapies are being developed for patients with severe monogenic central nervous system diseases, a global patient population, but the company's operations and clinical trials are based in the United States. The company was incorporated in 2019 and has since focused on advancing its pipeline of AAV-based gene therapies for rare neurological disorders.

Taysha Gene Therapies has a robust pipeline of AAV-based gene therapies targeting severe monogenic central nervous system diseases. The lead candidate is TSHA-120 for giant axonal neuropathy. Other notable programs include TSHA-102 for Rett syndrome, TSHA-121 for CLN7 disease, TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 deficiency, TSHA-113 for tauopathies, TSHA-106 for Angelman syndrome, and TSHA-114 for fragile X syndrome. These therapies are in various stages of clinical development, aiming to address significant unmet medical needs in rare neurological conditions.